A process for making sorbic acid from renewable materials is provided. The process comprises converting acetic acid to ketene; converting acetaldehyde to crotonaldehyde; reacting the ketene with the crotonaldehyde to produce a polyester; and converting the polyester to sorbic acid. Renewable materials are incorporated by one of the following methods: a) the acetic acid is produced by reacting methanol derived from renewable organic material with carbon monoxide, b) the acetic acid is a biobased acetic acid, c) the crotonaldehyde is a biobased crotonaldehyde, d) the crotonaldehyde is produced by converting a biobased acetaldehyde to crotonaldehyde, e) the crotonaldehyde is produced by converting acetaldehyde to crotonaldehyde and the acetaldehyde is produced from bioethylene, or any combination of a), b), c), d) and e).

A process for making sorbic acid from renewable materials is provided. The process comprises converting acetic acid to ketene; converting acetaldehyde to crotonaldehyde; reacting the ketene with the crotonaldehyde to produce a polyester; and converting the polyester to sorbic acid. Renewable materials are incorporated by one of the following methods: a) the acetic acid is produced by reacting methanol derived from renewable organic material with carbon monoxide, b) the acetic acid is a biobased acetic acid, c) the crotonaldehyde is a biobased crotonaldehyde, d) the crotonaldehyde is produced by converting a biobased acetaldehyde to crotonaldehyde, e) the crotonaldehyde is produced by converting acetaldehyde to crotonaldehyde and the acetaldehyde is produced from bioethylene, or any combination of a), b), c), d) and e).

The present disclosure discloses free form or base and salts of compound of formula (I). Said salts include adipate, benzenesulphonate, hydrobromide, fumarate, benzoate, methanesulfonate, L-malate, d-glyconate, sorbate, phosphate, sulfate, L-tartrate, p-methylbenzenesulphonate, citrate, hydrochloride, ethanesulfonate, 1-hydroxy-2-naphthoate, succinate, acetate, glutarate or L-pyroglutamate. The present disclosure also discloses the crystals of free form and above salts.

The present disclosure discloses free form or base and salts of compound of formula (I). Said salts include adipate, benzenesulphonate, hydrobromide, fumarate, benzoate, methanesulfonate, L-malate, d-glyconate, sorbate, phosphate, sulfate, L-tartrate, p-methylbenzenesulphonate, citrate, hydrochloride, ethanesulfonate, 1-hydroxy-2-naphthoate, succinate, acetate, glutarate or L-pyroglutamate. The present disclosure also discloses the crystals of free form and above salts.

Zinc and copper (II) salts of the general formula CH.sub.2═C(R.sup.1)COO-M-OCOR.sup.2 are disclosed, wherein M-Zn or Cu, R.sup.1—H or CH.sub.3, R.sup.2—C.sub.2-C.sub.25 alkyl, or R.sup.2—CO—O— group is crotonate, or sorbate, or linoleate, excluding the compounds: CH.sub.2═C(CH.sub.3)—COO—Zn—O—CO—C.sub.2H.sub.5, CH.sub.2═CH—COO—Zn—O—CO—C.sub.2H.sub.5, CH.sub.2═CH—COO—Cu—O—CO—C.sub.2H.sub.5, CH.sub.2═C(CH.sub.3)—COO—Zn—O—CO—(CH.sub.2).sub.4—CH.sub.3, CH.sub.2═CH—COO—Zn—O—CO—(CH.sub.2).sub.4—CH.sub.3, CH.sub.2═CH—COO—Zn—O—CO—(CH.sub.2).sub.6—CH.sub.3, CH.sub.2═C(CH.sub.3)—COO—Zn—O—CO—(CH.sub.2).sub.6—CH.sub.3, CH.sub.2═CH—COO—Cu—O—CO—(CH.sub.2).sub.6—CH.sub.3, CH.sub.2═CH—COO—Zn—O—CO—(CH.sub.2).sub.14—CH.sub.3, CH.sub.2═C(CH.sub.3)—COO—Zn—O—CO—(CH.sub.2).sub.16—CH.sub.3, CH.sub.2═C(CH.sub.3)—COO—Zn—O—CO-iso-C.sub.17H.sub.35, CH.sub.2═CH—COO—Zn—O—CO-iso-C.sub.17H.sub.35, CH.sub.2═C(CH.sub.3)—COO—Zn—O—CO—(CH.sub.2).sub.17—CH.sub.3. Salts of the general formula wherein R.sup.2—C.sub.2-C.sub.25 alkyl, or R.sup.2—CO—O— group is crotonate, or sorbate, or linoleate, are applicable as biocides.

Zinc and copper (II) salts of the general formula CH.sub.2═C(R.sup.1)COO-M-OCOR.sup.2 are disclosed, wherein M-Zn or Cu, R.sup.1—H or CH.sub.3, R.sup.2—C.sub.2-C.sub.25 alkyl, or R.sup.2—CO—O— group is crotonate, or sorbate, or linoleate, excluding the compounds: CH.sub.2═C(CH.sub.3)—COO—Zn—O—CO—C.sub.2H.sub.5, CH.sub.2═CH—COO—Zn—O—CO—C.sub.2H.sub.5, CH.sub.2═CH—COO—Cu—O—CO—C.sub.2H.sub.5, CH.sub.2═C(CH.sub.3)—COO—Zn—O—CO—(CH.sub.2).sub.4—CH.sub.3, CH.sub.2═CH—COO—Zn—O—CO—(CH.sub.2).sub.4—CH.sub.3, CH.sub.2═CH—COO—Zn—O—CO—(CH.sub.2).sub.6—CH.sub.3, CH.sub.2═C(CH.sub.3)—COO—Zn—O—CO—(CH.sub.2).sub.6—CH.sub.3, CH.sub.2═CH—COO—Cu—O—CO—(CH.sub.2).sub.6—CH.sub.3, CH.sub.2═CH—COO—Zn—O—CO—(CH.sub.2).sub.14—CH.sub.3, CH.sub.2═C(CH.sub.3)—COO—Zn—O—CO—(CH.sub.2).sub.16—CH.sub.3, CH.sub.2═C(CH.sub.3)—COO—Zn—O—CO-iso-C.sub.17H.sub.35, CH.sub.2═CH—COO—Zn—O—CO-iso-C.sub.17H.sub.35, CH.sub.2═C(CH.sub.3)—COO—Zn—O—CO—(CH.sub.2).sub.17—CH.sub.3. Salts of the general formula wherein R.sup.2—C.sub.2-C.sub.25 alkyl, or R.sup.2—CO—O— group is crotonate, or sorbate, or linoleate, are applicable as biocides.

The present disclosure provides co-crystals of a lithium benzoate compound and a co-former compound of Formula (I) ##STR00001##
Also provided herein are methods of preparing the co-crystals and uses thereof in treating and/or reducing the risk for neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, bipolar disorders, or neurogenerative disorders).

The present disclosure provides co-crystals of a lithium benzoate compound and a co-former compound of Formula (I) ##STR00001##
Also provided herein are methods of preparing the co-crystals and uses thereof in treating and/or reducing the risk for neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, bipolar disorders, or neurogenerative disorders).

Provided are co-crystals of a sodium benzoate compound and a co-former compound of Formula (I) ##STR00001##
Also provided herein are methods of preparing the co-crystals and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer's disease) or a glucose or lipid metabolic disorder (e.g., obesity, diabetes, hypercholesterolemia, hypertension, or hyperlipidemia).

Provided are co-crystals of a sodium benzoate compound and a co-former compound of Formula (I) ##STR00001##
Also provided herein are methods of preparing the co-crystals and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer's disease) or a glucose or lipid metabolic disorder (e.g., obesity, diabetes, hypercholesterolemia, hypertension, or hyperlipidemia).